Ciprofloxacin penetration into the pulmonary parenchyma in Japanese patients.
OBJECTIVE
To assess the degree of penetration of intravenous (i.v.) ciprofloxacin into the lung parenchyma resected for lung carcinoma in Japanese patients.


METHODS
Ciprofloxacin was given i.v. over 1 h to ten Japanese patients with non-small cell lung carcinoma. We took 1 g of normal lung parenchyma and 1 ml of blood serum for analysis when the lung was resected. Ciprofloxacin concentrations were determined by high-performance liquid chromatography.


RESULTS
The mean time from the end of ciprofloxacin administration to lung resection was 135 +/- 55 min (range, 75-223 min). The mean concentrations of ciprofloxacin in the lung parenchyma and blood serum were 4.9 +/- 2.0 microg/g (range, 2.1-7.9) and 1.5 +/- 0.7 microg/ml (range, 0.8-2.7). The mean tissue per serum concentration ratio was 3.6 +/- 2.2 (range, 1.9-8.7).


CONCLUSIONS
The concentrations of ciprofloxacin in the lung parenchyma after i.v. administration in Japanese patients were above the minimal inhibitory concentration for bacteria from at least 75 min until 4 h later.
Haraguchi
Shuji
S
Department of Surgery, Nippon Medical School Musashikosugi Hospital, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki, Kanagawa, 211-8533, Japan.
Hioki
Masafumi
M
Yamashita
Koji
K
Orii
Koan
K
Yamashita
Yasuo
Y
Kawamura
Jun
J
Takushima
Mina
M
Endo
Naoya
N
Koizumi
Kiyoshi
K
Shimizu
Kazuo
K
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D002851:Chromatography, High Pressure Liquid; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007564:Japan; D008168:Lung / Q000378:metabolism*; D008175:Lung Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D002939:Ciprofloxacin